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Nonselective NSAIDs with misoprostol or a PPI
instead of COX-2 inhibitor is a reasonable strategy
Although celecoxib is an effective NSAID, 
rofecoxib and lumericoxib are the only COX-2
selective inhibitors that definitively reduce 
gastrointestinal (GI) ulcerations/complications
compared with nonselective NSAID therapy.1,2
However, neither of these are on the market. 
Data from the CLASS study showed no reduced
risk of GI ulcerations/complications with celecoxib
vs ibuprofen or diclofenac among patients 
receiving low-dose aspirin.3 Low-dose aspirin
reduces cardiovascular events for patients with
moderate or high cardiovascular risk (Framingham
scores ≥10%). Therefore, using nonselective NSAID
therapy in combination with either misoprostol or
a proton pump inhibitor (eg, omeprazole) instead
of celecoxib, is a reasonable and proven strategy
to provide NSAID therapy for patients on low-dose
aspirin who are at high risk for NSAID-associated
gastropathy. 
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Cyclo-oxygenase-2 (COX-2) selective nonsteroidal
anti-inflammatory drugs (NSAIDs) are as effective as
acetaminophen and nonselective NSAIDs in treating
of osteoarthritis, and are equally effective in reduc-
ing pain and inflammation and improving of joint
function for patients with rheumatoid arthritis, when
compared with nonselective NSAIDs. The COX-2
selective NSAIDs also have a better gastrointestinal
safety profile in short-term (6–12 month) treatment
(strength of recommendation [SOR]: A, based on
meta-analysis of randomized controlled trials with
patient-oriented outcomes).
However, with recent growing concern of the
cardiovascular safety of COX-2 selective NSAIDs, 
it is imperative to select appropriate patients by
considering benefit vs risks, which include serious
gastrointestinal bleeding (TABLE 1), history of
intolerance to nonselective NSAID, cardiovascular
disease or associated risks, renal disease, patient’s
preference, and cost. 
C L I N I C A L C O M M E N T A R Y
■ Evidence summary
A Cochrane review4 (6 randomized con-
trolled trials, N=1689, mean duration 5.8
weeks) assessed the efficacy and safety of
acetaminophen in the management of
osteoarthritis, comparing it with placebo
and NSAIDs. Acetaminophen was superior
to placebo in pain reduction and global
assessment (number needed to treat
[NNT]=2) with a similar safety profile.
NSAIDs were better than acetaminophen
in pain reduction, patient (NNT=6) and
physician global assessment (NNT=17),
but no better for functional improvement.
Compared with nonselective NSAIDs, 
acetaminophen led to fewer withdrawals
(number needed to harm [NNH]=20) and
fewer GI adverse events (NNH=9), but
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there was no statistical difference when
compared with COX-2 selective NSAIDs.
Another Cochrane review5 (26 random-
ized controlled trials) found that rofecoxib
(Vioxx) was more effective than placebo
(NNT=5), and equally effective with other
NSAIDs in the management of osteoarthri-
tis. They reported fewer GI adverse events
(endoscopically observed gastric erosion
and ulcers) with rofecoxib than with other
NSAIDs—naproxen (Naprosyn), ibuprofen
(Motrin), diclofenac (Cataflam), nabume-
tone (Relafen), diclofenac/misoprostol
(Arthrotec), and nimesulide. However, the
withdrawal rate due to adverse events and
the increase in blood pressure and edema
were significantly greater with rofecoxib
than placebo at 6 weeks.
Two Cochrane reviews6–7 confirmed the
efficacy of celecoxib (Celebrex) and rofe-
coxib in treating of rheumatoid arthritis.
One review included 2 RCTs (N=8734)
with a placebo arm (8 weeks) and naprox-
en arm (9 months).7 The rofecoxib groups
(25 mg, 50 mg) had more responders than
the placebo group (NNT=8 and 6 respec-
tively). Compared with naproxen (1 g), no
difference was seen in efficacy in the
OMERACT outcomes (Outcome Measures
for Rheumatoid Arthritis Clinical Trials),
but all combined GI adverse events (perfo-
ration, ulcer, obstruction, bleeding, and all
episodes of GI bleeding) were significantly
reduced at 9 months (NNH=20). The with-
drawals were the same in the 3 groups.
Compared with placebo, the rofecoxib
groups had similar incidence of elevated
blood pressure and edema (NNH=50 and
100, respectively). Compared with the
naproxen group, no difference was seen in
renal adverse events, but total cardiovascu-
lar thrombotic events (NNH=200) and
nonfatal MI (NNH=300) increased at 9
months in the 50 mg rofecoxib group. 
Similar cardiovascular adverse events
were reported in the APPROVE trial.9 In
this study, patients taking rofecoxib 25 mg
daily for 18 months had increased total
thrombotic events (MI, stroke, peripheral
arterial and venous thrombosis, and pul-
monary embolism) when compared with
placebo (NNH=63). A recent study also
raised the same concern of increased car-
diovascular adverse events with celecoxib.10
This study demonstrated an increase risk of
cardiovascular events (combined death,
myocardial infarction, stroke, and heart
failure) for patients taking celecoxib 200
mg twice a day (NNH=77) or 400 mg
twice a day (NNH=42). 
Many patients taking low-dose aspirin
for cardioprotection also frequently require
treatment of pain and inflammation with a
NSAID. Even low-dose aspirin (75 mg/d) is
known to be associated with increased GI
toxicity (ulcers and hemorrhages).11 A
recent double-blind, randomized placebo-
controlled trial found that 12 weeks of
treatment with a combination of low-dose
aspirin and a COX-2 selective NSAID
(rofecoxib) had more than twice the inci-
dence of endoscopically confirmed gastric
and duodenal ulcers,  compared with
aspirin alone, and no difference with a non-
selective NSAID.12 This has raised the safe-
ty concern of concomitant use of a COX-2
selective NSAID with low-dose aspirin.
Recommendations from others 
The American Pain Society recommends
that for patients with osteoarthritis, aceta-
minophen is the drug of choice for mild
pain.13 For moderate to severe pain and or
inflammation, a COX-2 selective NSAID is
the first choice, unless the patient is at sig-
nificant risk for hypertension or renal dis-
order. For patients with active rheumatoid
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T A B L E 1
RISK FACTORS PRESENT RISK OF GI BLEEDING
0 factor 0.4 %
Any 1 factor 1.0 %
All 4 factors 9.0 %
Risk factors include age >75 years, history of peptic ulcer disease,
history of gastrointestinal bleeding, history of cardiovascular disease
Source: Silverstein et al, Ann Intern Med 1995.8
Prediction of serious gastrointestinal bleeding
T A B L E 2
Age ≥65 years  
Comorbid medical conditions  
Oral glucocorticoids  
History of peptic ulcer disease  
History of upper gastrointestinal bleeding   
Anticoagulants  
Source: American College of Rheumatology, 
Arthritis Rheum 2000.12
Risk factors for upper 
gastrointestinal adverse events
arthritis and moderate to severe pain with
or without inflammation, a COX-2 selec-
tive NSAID should be used con-
comitantly with a disease-modifying
antirheumatic drug (DMARD), unless con-
traindicated by existing uncontrolled
hypertension and renal disease. It further
recommends that for a person who is at
risk for a cardiovascular event, an aspirin
(75–160 mg/d), should be given along with
a COX-2 selective NSAID. 
The American College of Rheumatol-
ogy recommends that a COX-2 selective
NSAID should be considered for a person
with osteoarthritis and pain not relieved by
an adequate dose of acetaminophen (not
to exceed 4 g/d).14,15 The COX-2 selective
NSAID is particularly advantageous for
those who have higher risk factors for
adverse GI events (TABLE 2). For a person
with rheumatoid arthritis, in addition to
DMARDs, NSAIDs (salicylates, nonselec-
tive NSAID, or COX-2 selective NSAID)
should be used to reduce joint pain and
swelling and improve joint function.
Patients with additional risks for cardio-
vascular events should be cautioned about
use of a COX-2 selective NSAID. 
A recent AHRQ report on managing
osteoarthritis underscores the importance
of physician-patient partnership and
patient’s self management of osteoarthritis,
and recommends acetaminophen (up to 
4 g/day) as the drug of choice.16 It further
cautions the injudicious use of NSAIDs
because of its greater GI toxicity when
compared with acetaminophen, and its
higher medical costs. ■
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